Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

This review discusses various diagnostic and treatment strategies for canine prostate diseases, including pharmacological options and advanced procedures, but reports no new clinical results.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found that prostate size varies significantly among different ethnic groups in South-Kivu, with the Lega having larger prostate volumes compared to other groups.

This review highlights the potential of plant-derived molecules like Epigallocatechin-3-Gallate and Ginsenosides to promote healthy hair growth by enhancing nutrient supply and blood flow to the scalp, and notes their growing role in natural hair care product development.

This study found that in prodromal Alzheimer's disease, pro-inflammatory gut bacteria were associated with reduced cerebral blood flow and reactivity, while beneficial gut bacteria correlated with better outcomes.

This review compares mesotherapy and PRP for hair loss but reports no new clinical results; the authors highlight the need to understand their differences for optimal treatment choices.

This study found that patients with androgenetic alopecia had thinner scalp and subcutaneous tissues, narrower and shorter hair follicles, a lower hair follicle count, and fewer color flow signals compared to healthy volunteers, as measured by 22 MHz ultrasound.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This chapter reviews various in vitro and laboratory animal models for studying potential therapies for alopecia and reports no new results.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

This review discusses the role of finasteride preoperatively in reducing bleeding and complications during TURP and reports no new clinical results; the authors emphasize its potential benefits based on existing studies.

This review explores different types of alopecia, the effects on hair appearance and growth, and the conventional treatments available, including minoxidil and finasteride, along with their side effects and the need for future drug development and potential therapies.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.

This study examined the most common chemotherapy side effects among patients with prostate, bladder, and testicular cancer, noting hair loss, fatigue, and decreased appetite as frequent symptoms.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

This study found that men who began balding at age 20 were twice as likely to develop prostate cancer later in life compared to those who did not experience early hair loss.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

CEC levels may be a useful marker for predicting prostate cancer progression.

Gene variation affects prostate issues and hair loss.

This study observed that men with frontal and moderate vertex baldness between ages 40 and 50 had a higher risk of aggressive prostate cancer, suggesting a potential link between baldness pattern and cancer risk.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.

This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.